<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04338295</url>
  </required_header>
  <id_info>
    <org_study_id>2000027352</org_study_id>
    <nct_id>NCT04338295</nct_id>
  </id_info>
  <brief_title>Follicular Revival in Treatment-resistant Alopecia Areata: Evaluating Use of Micro-needling</brief_title>
  <official_title>Follicular Revival in Treatment-resistant Alopecia Areata: Evaluating Use of Micro-needling</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators propose to study the efficacy of micro-needling via the SOL Nova Device in&#xD;
      generating hair growth in patients with Alopecia Areta (AA) who are either non-responsive or&#xD;
      only partially responsive to combination oral JAK inhibitor plus oral minoxidil therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a trial evaluating the efficacy of micro-needling via tattoo device in&#xD;
      stimulating scalp hair growth in patients with AA refractory to combination JAK inhibitor and&#xD;
      oral minoxidil treatment. Ten healthy subjects who are at least eighteen years of age who&#xD;
      have experienced no or partial scalp hair regrowth after ≥three months of JAK inhibitor plus&#xD;
      oral minoxidil treatment will be enrolled. Subjects will undergo a treatment session once&#xD;
      every thirty days for a total of six sessions over six months and will complete a total of&#xD;
      eight visits over eight months. Procedures and visits are not standard of care but conducted&#xD;
      for research. Each visit will last about an hour. Approximately 30 minutes will be spent on&#xD;
      consenting and time for patient to ask questions during the first visit. The remaining 30&#xD;
      minutes will be allotted for the investigator to determine if the patient meets criteria for&#xD;
      trial enrollment. During the remaining visits, 20 minutes will be allotted for photography,&#xD;
      15-20 minutes for the procedure and 10-15 minutes for post-procedure patient assessment.&#xD;
      Remaining 10 minutes on visits 2 and 8 will be used for biopsy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">April 9, 2021</start_date>
  <completion_date type="Anticipated">October 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Device Feasibility</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Target area hair count (TAHC)</measure>
    <time_frame>6 months</time_frame>
    <description>Total number of hairs in the area that undergoes microneedling</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hair phase</measure>
    <time_frame>6 months</time_frame>
    <description>Number of catagen, anagen hairs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vellus hairs</measure>
    <time_frame>6 months</time_frame>
    <description>Number of vellus hairs in an area of 1cm^2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal hairs</measure>
    <time_frame>6 months</time_frame>
    <description>Number of terminal hairs in an area of 1cm^2</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Alopecia Areata</condition>
  <arm_group>
    <arm_group_label>Microneedling</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with Alopecia Areata will receive microneedling with a tattoo machine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Tattoo machine (SOL Nova Device)</intervention_name>
    <description>A SOL Nova Device (brand) tattoo machine will be used to stimulate hair regrowth.</description>
    <arm_group_label>Microneedling</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of AA&#xD;
&#xD;
          -  SALT score ≥90%&#xD;
&#xD;
          -  No or minimal scalp hair regrowth after ≥three months of oral JAK inhibitor plus oral&#xD;
             minoxidil treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known concomitant androgenetic or other form of alopecia (in addition to AA)&#xD;
&#xD;
          -  Patients with the following who would make poor candidates for microneedling such as&#xD;
             skin conditions, diabetes, or history of keloid formation&#xD;
&#xD;
          -  Anything additional existing comorbidities that in the opinion of the investigator may&#xD;
             cause unnecessary risk for the patient to participate&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brett King, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Associate Professor of Dermatology, Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 3, 2020</study_first_submitted>
  <study_first_submitted_qc>April 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2020</study_first_posted>
  <last_update_submitted>April 19, 2021</last_update_submitted>
  <last_update_submitted_qc>April 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alopecia</mesh_term>
    <mesh_term>Alopecia Areata</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

